A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of cytokine release syndrome (CRS) during Cycle 1 of elranatamab treatment following a single prophylactic dose of tocilizumab.

NCT Number	NCT07637578
Lead Sponsor	SCRI Development Innovations, LLC Collaborators: Pfizer
Conditions	Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Enrollment	46 participants
Start Date	2026-08
Primary Completion	2029-10 (estimated)
Study Completion	2030-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-11